Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma - Related Studies

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma

This study has been completed.

Study NCT00019175. Last updated on October 18, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Melanoma (Skin)

2	Additional conditions recognized in this trial
		Melanoma

3	More general conditions related to this trial
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms, Germ Cell and Embryonal
		Neoplasms, Nerve Tissue
		Neuroectodermal Tumors
		Neuroendocrine Tumors
		Nevi and Melanomas

4	Interventions listed in this trial
		aldesleukin
		fowlpox virus vaccine vector
		gp100 antigen

5	More general drug interventions related to this trial
		Anti-HIV Agents
		Anti-Infective Agents
		Anti-Retroviral Agents
		Antineoplastic Agents
		Antiviral Agents
		Pharmacologic Actions
		Therapeutic Uses

6	Sponsors listed in this trial
		NCI - Center for Cancer Research-Medical Oncology
		National Cancer Institute (NCI)